The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move signaling the continued momentum of e-commerce IPOs, iHerb has selected JPMorgan and Morgan Stanley to lead its initial public offering, which is expected to raise around $500 million, according to reports. The selection of two of the largest investment banks underscores the company’s push toward a public listing amid growing investor interest in the health-and-wellness sector.
Founded in 1996 in California, iHerb has grown into a global leader in online supplement and natural product retail. The underwriter picks come as the IPO market shows signs of recovery, with several tech and consumer companies eyeing listings. Competitors include Swanson and Amazon, but iHerb's international reach and strong brand loyalty set it apart.
Sign in to access this content
Sign InNo pricing date or valuation range has been announced yet; the company is expected to file a registration statement with the SEC in the coming months. Analysts will watch for valuation details given the current interest rate environment. Sentiment toward health-tech IPOs remains constructive, which could support a successful debut.